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We examined the causes for decreased glutathione (GSH) in individuals with HIV infection. We observed lower levels of
intracellular GSH in macrophages from individuals with HIV compared to healthy subjects. Further, the GSH composition found
in macrophages from HIV+ subjects heavily favors oxidized glutathione (GSSG) which lacks antioxidant activity, over free GSH
which is responsible for GSH’s antioxidant activity. This decrease correlated with an increase in the growth of Mycobacterium
tuberculosis (M. tb) in macrophages from HIV+ individuals. In addition, we observed increased levels of free radicals, interleukin-
1 (IL-1), interleukin-17 (IL-17) and transforming growth factor-β (TGF-β) in plasma samples derived from HIV+ individuals
compared to healthy subjects. We observed decreased expression of the genes coding for enzymes responsible for de novo synthesis
of GSH in macrophages derived from HIV+ subjects using quantitative PCR (qPCR). Our results indicate that overproduction of
proinﬂammatory cytokines in HIV+ individuals lead to increased production of free radicals. This combined with the decreased
expressionofGSHsynthesisenzymesleadstoadepletionoffreeGSHandmayleadinparttothelossofimmunefunctionobserved
in HIV patients.
1.Introduction
According to the World Health Organization (WHO), it is
estimatedthatapproximately33.3millionpeopleareinfected
with HIV, two-thirds of which live in sub-Saharan Africa.
It is also estimated that nearly 2.6 people are infected each
year [1]. People diagnosed with AIDS often suﬀer from life-
threatening diseases caused by opportunistic infections in-
cluding tuberculosis (TB). In recent years, there has been a
signiﬁcant increase in the incidence of TB due to the em-
ergence of multidrug and extreme-drug resistant strains of
M.tbandduetoincreasednumbersofhighlysusceptibleim-
munocompromised individuals arising from the AIDS pan-
demic. It is also believed that in developing countries, as
many as 40 to 80% of individuals with AIDS are at risk
of developing TB [2, 3]. In previous studies, our lab has
reported that the virulent strain of M. tb is sensitive to the
antioxidant, GSH [4–9]. Our studies have shown that HIV-
infected individuals have deﬁciencies of intracellular GSH in
red blood cells (RBC’s) as well as peripheral blood mono-
nuclear cells (PBMC’s), which include T cells, natural killer
cells, and monocytes [8].
GSHisatripeptidecomposedofglutamine,cysteine,and
glycine which plays a major role in the maintenance of the
intracellular redox state. GSH is also important for cellular
homeostasis as well as many diﬀerent cellular functions such
as protein synthesis, enzyme catalysis, transmembrane trans-
port, receptor action, intermediary metabolism, and cell
maturation [10–12] .G S Hi sp r o d u c e db yn e a r l ya l lc e l lt yp e s
and exists in two forms. Reduced or free GSH is responsible
for the antioxidant functions of GSH, while GSSG is the2 Clinical and Developmental Immunology
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Figure 1: (a) The ﬁrst step in de novo GSH biosynthesis is rate limiting. Glutamine and cysteine are linked by the homodimeric enzyme
glutamine-cysteine ligase, (b) GSS catalyzes the second step in GSH biosynthesis, linking glycine and γ-glutamyl cysteine to form GSH. (c)
Oxidized GSH can be converted to free GSH by GSR, utilizing NADPH as a cofactor.
byproduct of the free radical scavenging activity of GSH and
lacks antioxidant function [10–12].
Free GSH is synthesized in the cell via two diﬀerent
mechanisms.FreeGSHcanbesynthesizeddenovothrougha
two-stepprocesswhichismediatedbytwodiﬀerentenzymes.
The ﬁrst, and rate-limiting step in de novo GSH synthesis is
the linking of glutamine and cysteine by glutamine-cysteine
ligase (GCL) to form γ-glutamyl cysteine (Figure 1(a)). The
second step is the linking of glycine to γ-glutamyl cysteine
which is catalyzed by the enzyme glutathione synthase (GSS)
(Figure 1(b)). Free GSH can also be synthesized via the re-
duction of GSSG. This reaction is catalyzed by glutathione
Reductase (GSR) which utilizes NADPH as a cofactor
(Figure 1(c)).
It is our hypothesis that chronic HIV infection leads to
excessive production of proinﬂammatory cytokines such as
IL-1, IL-17, and TNF-α. The chronic overproduction of pro-
inﬂammatory cytokines leads to the generation of free
radicals. These free radicals are scavenged by free GSH. The
excessive production of free radicals in HIV-infected in-
dividuals will lead to the depletion of GSH. In addition, ele-
vated TGF-β blocks the production of GCLC which reduces
the production of new molecules of GSH. Elevated levels of
IL-1willalsofacilitatethelossofintracellularcysteine,which
further reduces the production of new GSH molecules.
We tested our hypothesis by performing in vitro studies
using human monocyte-derived macrophages isolated from
healthy individuals and individuals with HIV infection. OurClinical and Developmental Immunology 3
results signify an important mechanism that is responsible
for decreasing the levels of GSH in macrophages from in-
dividuals with HIV infection resulting in enhanced multipli-
cation and survival of intracellular M. tb.
2.MaterialsandMethods
2.1. Subjects. A total of 26 volunteers (13 healthy subjects
and13individualswithHIVinfection)wererecruitedforthe
study. Individuals with HIV infection were recruited from
the Foothills AIDS project. Healthy subjects without HIV
infection or a history of TB were recruited from the univer-
sity faculty and staﬀ. All HIV-infected volunteers had been
diagnosed with HIV-1, were taking some form of antiretro-
viral treatment (ART), and had CD4+ T-cell counts between
271 and 1415 cells per mm3. Thirty ﬁve milliliters of blood
was drawn once from both healthy volunteers and individu-
alswithHIVinfectionafterobtainingasignedinformedcon-
sent. All our studies were approved by both the Institutional
Review Board and the Institutional biosafety committee.
2.2.IsolationofMonocytesandInVitroCultureforDiﬀerentia-
tion to Macrophages. We ﬁrst isolated PBMC from the whole
blood of healthy and HIV-infected individuals using density
gradient centrifugation with FICOLL Histopaque (Sigma).
Plasma samples from healthy and HIV-infected subjects
were collected for cytokine measurement. Monocytes were
isolatedfromPBMCsbyadherencetopoly-Llysine(%0.005)
treated-96 well-tissue culture plates. Brieﬂy, PBMCs (1 ×
105 cells/well) were added to poly-L lysine-treated tissue cul-
ture plates and incubated overnight at 37◦C to facilitate mo-
nocyte adherence. Following overnight adherence, the non-
adherent cells were removed, and fresh media [RPMI
(Sigma) supplemented with 5% human AB serum (Sigma)]
was added to the adherent cells which were then incubated
for7daysincultureconditionstoallowthemonocytestodif-
ferentiate into macrophages.
2.3.AssayofIL-1,TGF-β,IL-17,andMalondialdehyde(MDA)
in Plasma and Macrophage Lysates. Cytokines were measur-
ed from collected plasma and macrophage culture super-
natants by enzyme-linked immunosorbent assay (ELISA)
(eBioscience). MDA was measured in macrophage lysates by
colorimetric assay (Cayman Chemical).
2.4. Assay of GSH Levels in Macrophages from Healthy and
HIV-Infected Subjects. GSH levels were measured in isolated
macrophages from healthy subjects and individuals with
HIV infection. Intracellular levels of GSH in macrophages
were determined by spectrophotometry using an assay kit
from Arbor Assays. Brieﬂy, macrophages (3 × 105)w e r e
detached from the culture plate by treatment with tryp-
sin (50μL/105 cells) for 10 minutes in culture conditions.
Detached cells were washed and resuspended in ice cold 5%
5-sulfosalicylic acid dehydrate solution (SSA). Supernatants
collected after centrifugation were analyzed for total and oxi-
dized GSH as per manufacturer’s instructions. Free GSH was
calculated by subtracting measured oxidized GSH concen-
trations from the measured total GSH concentrations, per
the manufacturer’s instructions. All GSH measurements
were normalized with total protein levels.
2.5. Assay of Total Protein Levels in Macrophage Supernatants
and Cell Lysates. Proteins in the isolated macrophage super-
natants and lysates were measured by Bradford’s method us-
ing a Coomassie protein assay reagent (Thermo Scientiﬁc).
2.6. Preparation of Bacterial Cells for Macrophage Infection.
All infection studies were performed using the virulent lab-
oratory strain of M. tb, H37Rv inside the biosafety level 3
(BSL-3) facility. M. tb was processed for infection as follows:
static cultures of H37Rv at their peak logarithmic phase of
growth(between0.5and0.8 atA600) wereusedforinfection
of monocytes. The bacterial suspension was washed and re-
suspended in RPMI (Sigma) containing AB serum (Sigma).
Bacterial clumps were disaggregated by vortexing ﬁve times
with 3mm sterile glass beads. The bacterial suspension was
passed through a 5μm syringe ﬁlter (Millipore) to remove
any further clumps. The total number of organisms in the
suspension was ascertained by plating. Processed H37Rv was
frozen as stocks at −80◦C. At the time of infection, frozen
stocks of processed H37Rv were thawed and used for mono-
cyte infection.
2.7. Infection of Macrophages with M. tb. Monocyte-derived
macrophages were infected with processed H37Rv at a mul-
tiplicity of infection of 10:1 and incubated for 2 hours for
phagocytosis. Unphagocytosed mycobacteria were removed
by washing the infected macrophages three times with warm
sterile PBS. Infected macrophages were cultured in RPMI +
5% AB serum. Infected cultures were terminated at 1 hour
and 5 days postinfection to determine the intracellular sur-
vival of H37Rv. Culture supernatants were collected, ﬁltered
through a 0.2μm ﬁlter, and stored at −80◦C for the assay of
cytokines.
2.8. Termination of Infected Macrophage Cultures and Mea-
surement of Colony Forming Units. The termination of M. tb
infected cultures was performed by the addition of 200μLo f
distilled sterile water to each culture well. The collected cell
lysates were plated on 7H11 medium (Hi Media) enriched
with albumin dextrose complex (ADC), to estimate the ex-
tent of H37Rv growth in macrophages.
2.9. Quantitative PCR Analysis of GSH Synthesis Genes. RNA
was isolated from macrophages from healthy and HIV-
infected individuals using Trizol (Invitrogen) per the man-
ufacturer’s instructions. Isolated RNA was quantiﬁed using a
NanoVuespectrophotometer(GE).IsolatedRNAwasreverse
transcribed to cDNA using a qScript cDNA synthesis kit
(Quanta Biosciences) per the manufacturer’s instructions.
qPCR analysis of gene expression was performed using an
EvaGreen qPCR master mix (Biotium) and primers for the
GSH-metabolism genes: glutamine-cysteine ligase (catalytic
subunit) (GCLC), glutamine-cysteine ligase (modulatory
subunit)(GCLM),glutathionesynthetase(GSS),glutathione
Reductase (GSR), and γ-glutamyl transferase 1 (GGT1)
(Elim Biopharmaceuticals) on a StepOne Plus thermocycler4 Clinical and Developmental Immunology
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Figure 2: (a) Assay of TGF-β in plasma from HIV-infected and healthy subjects. Plasma samples separated from blood of healthy volunteers
and HIV-infected individuals were used for measurement of TGF-β.L e v e l so fT G F - β in the plasma samples were determined by ELISA using
assay kits procured from eBioscience. Results in Figure 2 are averages of data collected from eight healthy subjects and twelve individuals
with HIV infection. Results show elevated TGF-β in HIV-infected subjects (∗P ≤ 0.05). (b) Assay of IL-1 in plasma from HIV-infected and
healthy subjects. Plasma samples separated from blood of healthy volunteers and HIV-infected individuals were used for measurement of
IL-1. Levels of IL-1 in the plasma samples were determined by ELISA using assay kits procured from eBioscience. Results in (b) are averages
of data collected from eight healthy subjects and twelve individuals with HIV infection. Results show elevated IL-1 in HIV-infected subjects
(∗P ≤ 0.05). (c) Assay of IL-17 in plasma from HIV-infected and healthy subjects. Plasma samples separated from blood of healthy volunteers
and HIV-infected individuals were used for measurement of IL-17. Levels of IL-17 in the plasma samples were determined by ELISA using
assay kits procured from eBioscience. Results in (c) are averages of data collected from eight healthy subjects and eight individuals with HIV
infection. Results show elevated IL-17 in HIV-infected subjects (∗P ≤ 0.05).
(ABI) per the manufacturer’s instructions. Using the ΔΔCt
method, comparative gene expression analysis was perform-
ed. Target gene expression was compared to the endoge-
nous control gene β-actin (ACTB) for each sample. Gene
expressionforeachtargetgeneinsamplesfromHIV-infected
subjects was compared to the expression observed in healthy
controls.
3. Results
3.1. Assay of Cytokines and MDA in Plasma and Macrophage
Supernatants. Measurement of IL-1 concentrations in the
plasma of healthy and HIV-infected individuals revealed a
signiﬁcant increase in the amounts of IL-1 present in the
plasma of HIV-infected individuals over those found in
healthy individuals. In fact, our study demonstrates a greater
than 6-fold increase in the plasma IL-1 concentrations
of HIV-infected individuals (Figure 2(b)). In addition, our
assay of IL-1 in the culture supernatants of macrophages
from HIV-infected and healthy individuals demonstrated a
signiﬁcantincreaseintheproductionofIL-1byHIV-infected
over uninfected macrophages (Figure 3(a)).
We also observed a signiﬁcant increase in the levels of
TGF-β in the plasma of HIV-infected individuals compared
to healthy subjects (Figure 2(a)). Assay of TGF-β in the sup-
ernatantsofmacrophageculturesalsodemonstratedasignif-
icant increase in the production of TGF-β by macrophages
from the HIV-infected group over those from the healthy
group (Figure 3(c)).
OuranalysisalsoincludedanassayofIL-17intheplasma
of our HIV and control groups. We found a signiﬁcant
elevation in the levels of IL-17 in the plasma from the
HIV-infected group in comparison to the control group
(Figure 2(c)).
Our comparison of TNF-α in the supernatants of HIV-
infected and healthy macrophages revealed a signiﬁcant
increase in TNF-α production by HIV-infected macrophages
(Figure 3(b)).
In addition to the cytokines mentioned above, we also
assayed the concentrations of MDA in the macrophage lys-
ates from healthy and HIV-infected subjects. MDA is a by-
product formed during lipid peroxidation. Measurement of
MDA has been shown to be a reasonably accurate represen-
tation of free radical formation [13, 14]. Our assay of MDA
revealed increased levels in the macrophage lysates of HIV-
infected individuals over healthy individuals (Figure 3(d)).
These elevated MDA levels correspond to elevated produc-
tion of free radicals.
3.2. Assay of GSH in Macrophage Lysates. Our analysis of
GSH in macrophage lysates demonstrated a marked decrease
in the total GSH present in HIV-infected macrophages
when compared to uninfected macrophages (Figure 4(a)).
In addition, our analysis of the GSH present in the tested
macrophage lysates demonstrated signiﬁcantly low levels ofClinical and Developmental Immunology 5
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Figure 3: (a) Assay of IL-1 in macrophage culture supernatants from HIV-infected and healthy subjects. Supernatants from human monocyte-
derived macrophages (from healthy and HIV-infected individuals) were assayed for the levels of IL-1 using assay kit from ebioscience. Data
in (a) denote means ± SE from eight healthy individuals and nine individuals with HIV infection (∗P ≤ 0.05). (b) Assay of TNF-α in
macrophage culture supernatants from HIV-infected and healthy subjects. Supernatants from human monocyte-derived macrophages (from
healthy andHIV-infectedindividuals) were assayed forthelevels ofTNF-αusingassaykit from ebioscience. Data in(b)are means ±SE from
eight healthy individuals and nine individuals with HIV infection (∗P ≤ 0.05). (c) Assay of TGF-β in macrophage culture supernatants from
HIV-infected and healthy subjects. Supernatants from human monocyte-derived macrophages (from healthy and HIV-infected individuals)
were assayed for the levels of TGF-β using assay kit from ebioscience. Data in (c) represent means ± SE from eight healthy individuals
and nine individuals with HIV infection (∗P ≤ 0.05). (d) Assay of MDA in macrophage lysates from HIV-infected and healthy subjects. Free
radical levels in macrophage lysates from healthy subjects and individuals with HIV infection were determined by measuring the levels of
MDA using a colorimetric assay kit from Cayman. Results in (d) are averages of data collected from ﬁve healthy subjects and ﬁve individuals
with HIV infection. These elevated MDA concentrations are indicative of elevated free radical concentrations. High standard error values
observed in HIV-infected subjects (a–d)are likely due to the varying stages ofHIV infection and antiretroviral treatment inthe HIV-infected
population.
free GSH in macrophages from individuals with HIV-infec-
tion when compared to macrophages from healthy subjects
(Figure 4(b)). Of particular interest are the relative percen-
tages of free GSH and GSSG. In macrophages isolated from
HIV-positive subjects, we observed the total GSH as being
composed of about 30% free GSH and 70% GSSG. In
macrophages isolated from healthy individuals, we observed
a GSH composition of about 60% free GSH and 40% GSSG
(Figure 4(c)).
3 . 3 .D e t e r m i n a t i o no ft h eI n t r a c e l l u l a rS u r v i v a lo fM .t bi n
Isolated Monocyte-Derived Macrophages. Our test for the
intracellular survival of M. tb in isolated macrophages
demonstratedgrowthofM.tbinthemacrophagesfromboth6 Clinical and Developmental Immunology
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Figure 4: (a) Assay of total GSH concentrations in macrophage lysates from HIV-infected and healthy subjects. GSH levels were measured in
isolated macrophages from healthy subjects and individuals with HIV infection by spectrophotometry using an assay kit from Arbor Assays.
Brieﬂy, an equal volume of ice cold 5% 5-SSA was added to the macrophage (3 × 105) pellet. Supernatants collected after centrifugation
were analyzed for total, and oxidized GSH as per manufacturer’s instructions. All GSH measurements were normalized with total protein
levels. Data in (a) represent means ± SE from ﬁve diﬀerent healthy and HIV-infected individuals. GSH concentrations are decreased in HIV-
infectedmacrophageswithrespecttohealthymacrophages(
∗P ≤ 0.05).(b)AssayoffreeGSHconcentrationsinmacrophagelysatesfromHIV-
infected and healthy subjects. Free GSH was calculated by subtracting measured oxidized GSH concentrations from the measured total GSH
concentrations,perthemanufacturer’sinstructions.Datain(b)denotemeans ±SEfromﬁvediﬀerenthealthyandHIV-infectedindividuals.
GSHconcentrationsaredecreasedinHIV-infectedmacrophageswithrespecttohealthymacrophages(
∗P ≤ 0.05).FreeGSHconcentrations
are decreased in HIV-infected macrophages with respect to healthy macrophages (
∗P ≤ 0.05). (c) A comparison of the composition of the
total GSH in healthy and HIV-infected subjects reveals that the majority of GSH in HIV-infected macrophages exists as oxidized GSH
(∼70%), whereas healthy macrophages contain a more balanced GSH makeup (∼40% oxidized, ∼60% free). (d) Intracellular growth of M. tb
in macrophages from healthy and HIV-infected individuals at 1 hour, and 5 days postinfection. Human monocyte-derived macrophages (from
healthy and HIV-infected individuals) were infected with the processed H37Rv at a multiplicity of infection of 10:1. Infected macrophages
were terminated at 1 hour and 5 days postinfection to determine the intracellular survival of H37Rv inside macrophages from healthy and
HIV-infected individuals. Macrophage lysates were plated on 7H11 medium enriched with ADC to estimate the growth or killing of H37Rv.
Results shown in (d) are averages from n = 4H I Va n dn = 5 healthy. Each experiment was performed in triplicate. Macrophages from
HIV-infected subjects demonstrate a markedly decreased ability to control intracellular M. tb growth.Clinical and Developmental Immunology 7
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Figure 5: Relative gene expression for the speciﬁed target genes
in comparison to the endogenous control ACTB. A comparison
of gene expression in macrophages from healthy and HIV-infect-
ed subjects demonstrates reduced gene expression for all genes
involved in the de novo synthesis of GSH in macrophages from
HIV-infected subjects. A greater than 3-fold increase in GSR ex-
pression is observed in HIV-infected macrophages. Results are from
n = 3 individuals for both healthy and HIV-infected macro-phages.
healthy and HIV-infected macrophages; however, there was
several-fold increase in the growth of M. tb in macrophages
from HIV-infected subjects. In fact, there was over 3 times
the M. tb growth in HIV-infected macrophages when com-
pared to healthy macrophages (Figure 4(d)). These results
conﬁrm that the ability of the macrophages collected from
HIV-infected subjects to control infections is impaired.
3.4. Comparative Gene Expression Analysis of GSH Synthesis
Enzymes. Comparative gene expression analysis of GCLC,
GCLM, GSS, and GGT1 in macrophages from HIV-infect-
ed subjects demonstrated a signiﬁcant reduction in the
expression of these genes when compared to healthy macro-
phages. Expression of GCLC and GCLM in HIV-infected
macrophages was reduced by about half. Expression of GSS
in HIV-infected macrophages was reduced by about 89%.
Interestingly, GSR expression in HIV-infected macrophages
was increased by a factor of 3.8 over GSR expression in
macrophages isolated from healthy subjects. Finally expres-
sion of GGT1 in HIV-infected macrophages was found to
be reduced by about 80% compared to healthy macrophages
(Figure 5).
4. Discussion
M. tb remains one of the most pernicious and an enduring
pathogen of mankind. It is inferred that the ﬁrst infected
cell is the alveolar macrophage that internalizes the bacilli
following inhalation of droplets aerosolized by infected
individuals [15]. The macrophage is known to be the pri-
marydefensemechanismagainstmicrobialinvasion[16,17].
Macrophages have a phagocytic system that delivers the mi-
crobe into a compartment, that is, the site of generation of
reactive oxygen intermediates, increasing acidity, hydrolytic
activity, and the presence of antimicrobial peptides [15].
Importantly, we reported that GSH plays a key role in
limiting intracellular growth of H37Rv in both human and
murine macrophages [4–6]. Thus, GSH has direct antimy-
cobacterial activity distinct from its role as an NO carrier,
functioning as an eﬀector molecule in innate defense against
M. tb infection [4–6]. These results unfold a novel and
potentially important innate defense mechanism adopted
by human macrophages to control M. tb infection [5, 6].
Consistent with these observations, we have also found that
GSH in combination with cytokines, such as IL-2 and IL-12,
enhance the activity of natural killer cells to control M. tb
infection inside human macrophages [7]. Importantly, data
from our most recent studies indicate that GSH activates the
functions of T lymphocytes to control M. tb infection inside
human monocytes (unpublished). All these observations
support the fact that GSH controls M. tb infection by func-
tioning as an antimycobacterial agent as well by enhancing
the functions of immune cells. Finally, we demonstrated that
GSH levels are signiﬁcantly reduced in PBMC isolated from
individuals with HIV infection, and this decrease correlated
with increased production of proinﬂammatory cytokines
and enhanced growth of M. tb [8].
In this study, we examined the causes for decreased GSH
in individuals with HIV infection. Furthermore, we also
characterized the eﬀects of decreased GSH in impairing the
growth inhibition of M. tb inside macrophages.
Measurement of IL-1 and TGF-β concentrations in the
plasma and macrophage supernatants of healthy and HIV-
infected individuals revealed a signiﬁcant increase in the
amounts of these cytokines present in HIV-infected indi-
viduals over healthy individuals. IL-1 is a proinﬂammatory
cytokine, when bound to its receptor, and transduces a signal
that initiates expression of a wide variety of inﬂammatory
genes via the NF-κB system. The subsequently transcribed
genes can produce a variety of inﬂammatory products in-
cluding chemokines, and proinﬂammatory cytokines, such
as TNF-α, IL-6, or IL-8 [18]. IL-1 and TNF-α have been
shown to be produced by either the binding of gp120 to
the CD4 molecules on mononuclear phagocytes or infection
with HIV [19, 20]. Several studies have demonstrated a
link between increased TGF-β production and decreases in
GCLC gene expression, as well as synthesis of GSH [21,
22]. In addition, we observed signiﬁcant increases in the
production IL-1 and TGF-β in the supernatants of macro-
phage cultures from the HIV-infected group compared to
healthy individuals (Figures 3(a) and 3(c)).
We also observed a signiﬁcant increase in the levels of IL-
17 in plasma samples from individuals with HIV-infection.
IL-17 is thought to play a signiﬁcant role in activating and
inducing antimicrobial peptides and proinﬂammatory cy-
tokines like IL-6, CCL2, and TNF-α [23, 24]. Furthermore,
high levels of this cytokine have been linked to a number
of inﬂammatory diseases including rheumatoid arthritis,
multiplesclerosis,andasthma.Lowlevels,ontheotherhand,
are thought to cause both impaired host defense against my-
cobacterial infection and decreased antibacterial immunity
[23, 25].8 Clinical and Developmental Immunology
Studies on the eﬀects of HIV on IL-17 concentrations
using ﬂow cytometry have found that HIV-infected patients
have signiﬁcantly increased levels of IL-17 [26]. However,
Brenchley et al. [25] noted that there were signiﬁcantly fewer
IL-17 producing Th17 cells in the gastrointestinal tract of
HIV-infected patients. In fact, the study indicated that Th17
cells were preferentially targeted during HIV infection. The
decrease of IL-17 concentrations at the mucosal wall of the
gastrointestinal tract could greatly increase the probability
of bacterial infections, which could in turn have signiﬁcant
implications for the speed of HIV pathogenesis [26]. As
Levy noted [27], chronic immune activation increases the
productionofproinﬂammatorycytokines(IL-6,IL-17,TNF-
α, etc.). This upregulation of proinﬂammatory cytokines
often leads to the rapid loss of CD4+ T cells via apoptosis.
We observed a signiﬁcant increase in the production of
TNF-α in the supernatants of macrophage cultures from
the HIV-infected group compared to healthy individuals
(Figure 3(b)). Moreover, in a separate study, we have ob-
served signiﬁcantly increased concentrations of TNF-α in
the plasma of HIV-infected subjects (unpublished). TNF-α,
another proinﬂammatory cytokine which plays a major role
in HIV infection, is produced by monocytes, macrophages,
and natural killer cells in response to HIV infection [19, 20].
There is correlation between HIV viremia and TNF-α and
IL-1 levels in the serum of HIV-infected patients. Excess pro-
duction of TNF-α may lead to inﬂammatory damage and
toxicity, which couldlead to degradation of the host immune
response independent of CD4+ T cell depletion. These high
levels of TNF-α contribute to fever, anorexia, and other
symptoms of HIV/AIDS. As HIV causes chronic infection,
this leads to the prolonged production of IL-1 and TNF-α,
which stimulate the prolonged production of free radicals.
This chronic state of inﬂammation leads in turn to chronic
oxidative stress [19, 20].
OurassayofMDArevealedincreasedlevelsinthemacro-
phage lysates of HIV-infected individuals over healthy indi-
viduals(Figure 3(d)). These elevated MDA levels correspond
to elevated production of free radicals. Furthermore, in a
previous study, we demonstrated signiﬁcantly elevated levels
of MDA in plasma isolated from HIV-infected individuals
over plasma from healthy individuals (unpublished).
We observed a signiﬁcant decrease in both the total and
free GSH present in macrophages from individuals with HIV
infection compared to macrophages from healthy subjects
(Figures 4(a) and 4(b)). We also observed an increased per-
centage of GSSG in macrophages from individuals with HIV
infection compared to macrophages from healthy subjects
(Figure 4(c)).
The decrease in the levels of both total and free GSH
correlated with several-fold increase in the growth of M. tb
inside macrophages from individuals with HIV infection
(Figure 4(d)). These results conﬁrm that the ability of the
macrophages derived from HIV-infected subjects to control
M.tbinfectionisimpaired.Theimmunocompromisedstatus
of the HIV-infected macrophages correlates with the in-
creased levels of proinﬂammatory cytokines, TGF-β,a n dd e -
creased levels of GSH.
Chronic oxidative stress is commonly observed in HIV
patients, indicating a beneﬁt for increased antioxidant
supplements which may reduce DNA damage, possibly
slowing the progression of infection [28]. The progression
of HIV infection is characterized by a loss of CD4+ Tc e l l s
and decreased immunity. Prolonged free radical overload
of monocytes and granulocytes in combination with the
decreasedproductionofGSHsynthesisenzymesindicatedby
our experiments contribute to the deﬁciency of antioxidant
mechanisms, GSH in particular. This may lead to the loss of
CD4+ T cells often seen in the progression of HIV [28–30].
We observed a signiﬁcant reduction in the expression
of GCLC, GCLM, GSS, and GGT1 genes in macrophages
from individuals with HIV infection compared to healthy
subjects. As most cells are unable to transport GSH or GSSG
across the plasma membrane, these compounds must be ﬁrst
cleavedattheγ-glutamylbondbeforetheycanbetransferred
into the cytosol [10, 31]. GGT1 performs this cleavage,
allowing the components for new GSH molecules to be
transferred into the cell [11, 12]. The reduction in GGT1
expressionweobservedwouldindicateareductionintheraw
materials necessary for de novo GSH production, also con-
tributing to GSH deﬁciency. Interestingly, GSR expression in
HIV-infected macrophages was increased by a factor of 3.8
over GSR expression in macrophages isolated from healthy
subjects. This increased GSR expression indicates an attempt
by the cell to increase free GSH concentrations through the
reclamation of oxidized GSH. However; since the produc-
tivity of this enzyme is limited by the amount of oxidized
GSHpresentandrequiresNADPHasacofactor,thisincrease
in GSR does not appear to be enough to compensate for the
decrease in de novo GSH production.
To summarize, we observed a signiﬁcant increase in the
levels of proinﬂammatory cytokines such as IL-1, TNF-α,
and IL-17 in individuals with HIV infection (Figures 2 and
3). This increase in the levels of proinﬂammatory cytokines
in individuals with HIV infection correlated with increased
production of free radicals (Figure 3). Additionally, we also
observed a signiﬁcant increase in the levels of TGF-β in both
plasma and macrophage supernatants from individuals with
HIV infection, and this increase correlated with reduction in
the expression GCL gene in macrophages (Figures 2, 3,a n d
5). The results of our studies indicate that increased levels
of free radicals (induced by proinﬂammatory cytokines) and
decreased expression GCL (induced by TGF-β)m a yc a u s e
decrease in the levels of GSH in macrophages derived from
individualswithHIVinfection.Importantly,decreasedlevels
of GSH in macrophages from individuals with HIV infection
is accompanied by enhanced intracellular survival of M. tb.
To conclude, we observed a correlation between decreas-
ed intracellular GSH levels, increased proinﬂammatory cy-
tokines, and increased free radicals. Our data supports our
hypothesis that decreased intracellular GSH levels in HIV-
infected individuals is a result of chronic overproduction
of inﬂammatory cytokines (IL-1, TNF-α and IL-17), and
cytokines (TGF-β) which interfere with the biosynthesis of
GSH (Figure 6). Our data also supports the idea that chronic
inﬂammation leads to increased production of free-radicals,
which in turn promote production of proinﬂammatory cy-Clinical and Developmental Immunology 9
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Figure 6: Model illustrating the reasons for decreased levels of GSH in macrophages from individuals with HIV infection.
tokines, and thus further depletion of intracellular GSH, and
increased production of free radicals. We believe that this is
a self-promoting loop of inﬂammation. In future studies, we
hope to demonstrate that this loop can be broken by sup-
plementing GSH. If successful, our data would indicate the
possibility of eﬃcacy for supplemental GSH therapy in in-
dividuals with HIV and M. tb coinfection.
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